March 13 (Reuters) - The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company said on Wednesday. (Reporting by Puyaan Singh, Pratik Jain and Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.3 USD | +1.98% | +8.63% | -10.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.91% | 1.22B | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- US FDA approves expanded use of Mirum's liver disease drug